Claudia Ulbrich (Cardior Therapeutics)
August 25, 2021 05:00 AM EDTUpdated 09:18 AM
Financing

A Bris­tol My­ers-backed biotech wants to treat heart dis­ease with non-cod­ing RNAs. It's one step clos­er to proof-of-con­cept

Max Gelman

Senior Editor

Is it pos­si­ble to use strands of non-cod­ing RNA, a bur­geon­ing ther­a­peu­tic area that re­searchers now be­lieve plays an im­por­tant part in how sim­i­lar genes …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

Bris­tol My­ers re­veals more job cuts in New Jer­sey

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Mer­ck halts Phase 3 tri­al with PAH drug Win­re­vair fol­low­ing pos­i­tive in­ter­im da­ta 

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

Cas­sa­va shares plunge as con­tro­ver­sial Alzheimer’s drug fails Phase 3 tri­al

A service from the Financial Times